CHAMGAP
VERIFIEDPassed the Codex final verification and publication gate. Evidence-verification cutoff: 2026-07-17. AI was used for research and drafting; the existence of all 3 cited sources was verified at the original page, followed by blind grading, adversarial audit, and build validation. Methodology v1.0.
Verdict No. 406 · Search date 2026-07-17 · Methodology v1.0

Apigenin,
does it really help with Sleep, relaxation, and anxiety relief?

30-Second Summary
?
Evidence Grade ? · Safety unknown
Chamomile studies are not clinical trials of isolated apigenin tablets
What the
research shows
No human sleep trial of isolated apigenin was identified. Human studies used multi-constituent chamomile extracts, and efficacy of a chamomile intervention cannot be attributed to isolated apigenin tablets. The verdict remains unclassified.
What the
ads claim
GABA-A binding, a natural sleeping pill, podcast sleep stacks, and 50 mg before bed convert mechanism and popularity into claims of clinical efficacy. Receptor binding is not the same as improved human sleep.
*

Useful facts when choosing a product

  • Fifty-milligram capsules are distributed through Korean online stores and cross-border shopping.
  • A marketed instruction of 50 mg before bed is not an efficacy dose established by clinical trials.
  • Apigenin exposure and co-constituents in chamomile extracts differ from an isolated 50 mg tablet.
  • Long-term human safety and interaction data with sleep medicines are insufficient; pregnancy, lactation, sedatives, and anticoagulants warrant professional review.
ID

Chamgap Semantic Classification Code

Candidate index · review held

S.apigenin.UNK.sleep-relaxation-and-anxiety-relief.relieve.UNK

Supplements and nutraceuticals > Apigenin > Unknown > Sleep, relaxation, and anxiety relief > Symptom-relief claim > Unknown

An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.

Download semantic index (JSON) · Codebook v1

Gap Measurement · Verdict 406 · ?
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Viola 1995 and related work concern receptor binding and mouse behavior. Human sleep evidence summarized by Kramer 2024 tested apigenin-containing chamomile extract rather than isolated apigenin. Effects of the multi-constituent chamomile intervention were therefore not extrapolated to an isolated apigenin supplement.

02

Why this is classified as ?

There is no human sleep trial of isolated apigenin, and multi-constituent chamomile is not ingredient-equivalent, so the verdict remains unclassified without a score.

Counterpoint. The question mark does not reject preclinical plausibility; it means human data are absent for the consumer sleep and anxiety claims.

Rejudgment record. Reassessment (cross-check reflected) — No human sleep trial of isolated apigenin exists, and multi-constituent chamomile interventions are not equivalent to isolated apigenin

✓

Cross-check — AI research and Codex final gate

AI was used for research and drafting. Blind grading, adversarial audit, and the methodology boundary rules were then reapplied before Codex performed the final evidence, grade, copy, and build checks. If a grade cannot be narrowed, both evidence positions and their reasons are published.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Viola et al. 1995Receptor-binding and mouse behavioral preclinical studyMice and in vitro assaysUnverifiedBenzodiazepine-receptor binding and elevated plus mazeAn anxiety-like behavior signal in mice, not a human sleep or anxiety outcome.Mechanistic support
Kramer and Johnson 2024Narrative review of sleep and agingPreclinical studies and human chamomile studiesAuthors affiliated with Tally HealthSleep mechanisms, animal behavior, and scope of human evidenceExplicitly states that human studies of apigenin alone are needed.Confirms evidence gap
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-07-17).

Kramer DJ, Johnson AA. Apigenin: a natural molecule at the intersection of sleep and aging. Front Nutr. 2024;11:1359176. PMID: 38476603. DOI: 10.3389/fnut.2024.1359176.
checked
Viola H, Wasowski C, Levi de Stein M, et al. Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Med. 1995;61(3):213-216. PMID: 7617761. DOI: 10.1055/s-2006-958058.
checked
Avallone R, Zanoli P, Puia G, Kleinschnitz M, Schreier P, Baraldi M. Pharmacological profile of apigenin, a flavonoid isolated from Matricaria chamomilla. Biochem Pharmacol. 2000;59(11):1387-1394. DOI: 10.1016/S0006-2952(00)00264-1.
checked
Research and draft: AI used · Cross-check: blind grading and adversarial audit
Final verification and publication gate: Codex · Evidence date: 2026-07-17 · Corrections: none
↗

Cite this verdict

Apigenin x sleep, relaxation, and anxiety relief Evidence Grade ? card
[Chamgap] Apigenin x sleep, relaxation, and anxiety relief — Evidence Grade ?. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/sleep/apigenin-sleep-relaxation-anxiety/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.
↑